Ista Pharmaceuticals has
introduced a new Bromday (bromfenac ophthalmic solution) 0.09% Twin Pack, containing two 1.7-mL bottles, allowing surgeons to write one prescription for two bottles covering two surgeries.

The Twin Pack was developed in response to physicians’ requests for greater patient convenience and fewer call-backs associated with bilateral cataract surgery. Depending on their insurance plan, patients may also benefit from a single co-pay. As always, clinicians should specify Dispense as Written, Do Not Substitute or Brand Medically Necessary, depending on applicable state law, to ensure their Bromday prescriptions are filled appropriately. The Bromday Twin Pack is available by prescription now (NDC# 67425-999-34).

Bromday is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. It is the only q.d. ophthalmic NSAID for use in cataract surgery. For information, visit

Eliminate Subjectivity from Low-Vision Testing
M&S Technologies has released eLVT, a new methodology for low-vision testing. The system was co-produced and engineered by Ian Bailey, OD, of UC Berkeley and M&S Technologies. This automated protocol delivers accuracy and repeatability, eliminating all subjectivity, technician bias and varied interpretation of subject responses, the company says. eLVT operates seamlessly with any M&S Smart System product or can be used as a stand-alone product for clinical trials and/or research and development.

The system offers visual acuity threshold to 20/20,000, the ability to test at several distances, and quick results that can be printed and/or stored digitally. It eliminates the need to count fingers or detect hand motion, allowing the clinician to determine the visual thresholds of low-vision patients with accuracy and repeatability.

For information, visit

B + L and Technolas Launch Victus Femto Platform
Bausch + Lomb and Technolas Perfect Vision GmbH introduced the Victus Femtosecond Laser Platform at ESCRS 2011. The Victus platform is a first-of-its-kind technology, capable of supporting cataract, refractive and therapeutic procedures in a single platform, the companies say. The versatile platform is designed to enable greater precision compared to manual cataract surgery techniques, potentially enhancing the patient experience.

The companies are working with regulatory authorities around the world to secure marketing approvals for the new platform and, as previously announced, will promote the system globally, leveraging their combined cataract and refractive expertise and commercial capabilities.
The Victus platform, along with early clinical data, will also be presented this month at the American Academy of Ophthalmology Annual Meeting in Orlando, Fla. For information, visit